Osteoporosis  /  Innovative Medical Research

More than 54 million Americans face the threat of osteoporosis; which causes more than 2 million fractures each year. These fractures can have a profound impact on quality of life—often leading to pain, disability, loss of independence, and even death—and cost the U.S. an estimated billion each year. Fortunately, scientists are continuing to make exciting breakthroughs that are helping to keep bones healthy and prevent debilitating fractures. The Alliance for Aging Research partnered with the National Osteoporosis Foundation to produce this volume.

28 Matching Facts

Search matching Facts:
No results to display
    • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the costs of care for all people with the disease by…  
    • 30 drugs are currently in development for osteoporosis.  
    • A recent study found that more postmenopausal women who took the drug denosumab gained at least 3% of bone mass at the hip and spine than those who took…  
    • A systematic review of osteoporosis therapies found good evidence that many are effective in preventing fractures, but concluded that the data are insufficient to determine if any one therapy is…  
    • Patients with vertebral fractures who underwent kyphoplasty, a procedure that stabilizes fractures of the spine, were found in one study to have reduced pain, fewer new fractures, and less healthcare…  
    • Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to decrease vertebral fractures by up to 50% after 3 years.  
    • Alendronate, a bisphosphonate, has been shown to reduce risk of hip fracture by around 53%, clinical vertebral fracture by 45%, and wrist fracture by 30%.  
    • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.  
    • Risedronate, a bisphosphonate, has been shown to reduce vertebral fractures by around 41%, hip fractures by 30%, and non-vertebral fractures by 39%.  
    • Ibandronate, a bisphosphonate, taken daily has been shown to reduce the risk of new vertebral fractures by around 62%.  
    • Treatment with zoledronic acid over a 3-year period reduced risk of vertebral fracture by around 70% and risk of hip fracture by 41%, and increased bone mineral density (BMD) by…  
    • A study that looked at a combination of calcium and Vitamin D found that hip fractures were reduced by around 43%.  
    • A meta-analysis of clinical trials found that Vitamin D supplements reduced the risk of vertebral fractures by around 37%.  
    • A meta-analysis of clinical trials found that calcium supplements reduced the risk of vertebral fractures by around 23%.  
    • A study of a number of osteoporosis treatments found cost-effectiveness ratios as low as $55,000 per QALY.  
    • The Study of Osteoporotic Fractures, which began over 20 years ago, found that bone mineral density (BMD) of the hip is one of the best predictors of fracture for women,…  
    • Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.  
    • Teriparatide, or human recombinant PTH, has been shown to increase vertebral bone mineral density (BMD) by 9% to 13%.  
    • Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.  
    • Randomized controlled trials give evidence that pharmacologic therapy can reduce risk of fractures by 40 to 50%.  
    • Clinical studies in nutrition and physical activity interventions have proven that fractures can be prevented, even in older individuals, and that they do not need to be a natural consequence…  
    • Treatment with bisphosphonates are highly cost-effective in women over the age of 70 with osteoporosis and a previous fracture.  
    • Hip fracture prevention in at-risk, postmenopausal women saves $333 million annually.  
    • Researchers are looking at the use of micro-computed tomography and magnetic resonance imaging to better understand the relationship between bone structure and fracture risk. Other tools are being evaluated for…  
    • Genetics can account for up to 75% of bone mineral density (BMD). Researchers have identified a gene that strongly influences peak bone mass in mice. The gene was not previously…  
    • Teriparatide, or human recombinant PTH, has been shown to decrease vertebral fractures by 65% to 69%, and non-vertebral fragility fractures by around 53%.  
    • Reducing risk of fracture from 8% to 2% reduces the 5-year fracture incidence from approximately 34% to 10%.  
    • An increase in bone mineral density (BMD) testing and osteoporosis treatment was associated with a decrease in hip fracture incidence.